Prostatic acid phosphatase: a possible diagnostic marker of ...
Recommend Documents
May 21, 2013 - the PSD oligonucleotide in the DNA-protein complex formation [123]. ..... disease-free and cancer-specific survival following anatomic radical retropubic .... Available online: http://www.ncbi.nlm.nih.gov/protein/AAI46094.
At the active site of rat prostatic acid phosphatase. (rPAP), residueAspm is a suitable candidate to act as an acidhase catalyst during phosphoester hydrolysis. It.
The steady-state kinetics of hydrolysis reaction catalysed by human prostatic acid phosphatase (PAP) by using 1-naphthyl phosphate, phenyl phosphate and ...
Jun 27, 2016 - Atsuko Yamamoto, Mari Furui, Akihiro Ohishi, Kazuki Nagasawa* ..... Taruno A, Vingtdeux V, Ohmoto M, Ma Z, Dvoryanchikov G, Li A, et al.
Mar 31, 2011 - leucel-T is a United States Food and Drug Ad- ministration .... sipuleucel-T required subjects to have a tumor specimen submitted to a central ...
Jun 8, 1982 - immunoassay may help further discriminate those patients requiring needle .... Analytical recovery data for the three PAP/RIA methods. Col.
Feb 28, 2017 - and expression of the recombinant PAP-IgM Fc fusion protein were confirmed in each tested the first, ... 1. February 2017 | Volume 8 | Article 274 .... 95â¦C and 10 s at 60â¦C. The elongation factor 1-α (EF-1α) gene was used as a .
Feb 6, 2009 - a Human Retrovirus Associated with Prostate Cancer ...... Research, the Prostate Cancer Foundation, the Charlotte Geyer Foun- dation, the ...
We compared results of measurement of prostatic acid phosphatase activity in serum and various tissues by en- zymatic assay and radioimmunoassay.
Human prostatic acid phosphatase (hPAP) was discovered in the 1920s [1]. It has been of significant medical interest ever since tests for the screening of serum ...
Jan 20, 2011 - HIV-1 Enhancing Effect of Prostatic Acid Phosphatase. Peptides Is Reduced in Human Seminal Plasma. Julie A. Martellini1, Amy L. Cole1, ...
Apr 14, 2016 - to the classical âtwo hitsâ Knudson's hypothesis for tumour suppressors, PTEN haploinsufficiency, or even a partial loss of its activity/expression ...
Prostatic acid phosphatase in serum and semen of dogs. Fosfatasa ácida prostática en suero y semen de perros. CRF Gadelha*, WRR Vicente, APC Ribeiro, ...
Department of Animal Obstetrics and Reproduction, Faculty of Veterinary and Agriculture ... diagnóstico de alteraciones en estos tejidos y para la inmunoterapia.
acid phosphatase, alkaline phosphatase, gamma glutamyltransferase and testosterone level in rats exposed to gasoline vapours. *F. E. Uboh, M. I. Akpanabiatu, ...
Apr 22, 2002 - Prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA) are the mark- ers of human prostatic gland. However, it is still not ...
41/5, 641-643 (1995). CLINICAL CHEMISTRY, Vol. 41, No. 5, 1995 641. Tartrate-Resistant Acid Phosphatase as a Marker of Bone Resorption. The application.
Tartrate resistant acid phosphatase as a marker for scale resorption in rainbow trout, Oncorhynchus mykiss: effects of estradiol-17p treatment and refeeding.
Oct 24, 2014 - Abstract. Tartrate-resistant acid phosphatase 5b (TRACP 5b) has been used as a biomarker of bone resorption and cancer metastasis. TRACP ...
Enzymatic Prostatic Acid Phosphatase in the Clinical. Staging of Patients Diagnosed With Prostate Cancer. Gregory S. Merrick, M.D.. Schiffler Cancer Center ...
The major secreted isoenzyme of human prostatic acid phosphatase (PAcP) (EC 3.1.3-2), which catalyses p-nitrophenyl phosphate (PNPP) hydrolysis at acid pH ...
Serum concentrations of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) were measured in 51 liver cirrhosis, 37 chronic active hepatitis.
Jan 13, 2010 - functioned as an ectonucleotidase with relative specificity adeno- sine 59-monophosphate [17,18]. There are two isoforms of PAP, a secreted ...
Prostatic acid phosphatase: a possible diagnostic marker of ...
Prostatic acid phosphatase (PAP): a possible diagnostic marker of intravascular large B-cell lymphoma. Background and objective: Intravascular large B-.
haematologica online 2004
Prostatic acid phosphatase (PAP): a possible diagnostic marker of intravascular large B-cell lymphoma Background and objective: Intravascular large Bcell lymphoma (IVL) has been treated as fever of unknown origin (FUO), and many patients have been treated inadequately based on incorrect diagnoses. We previously experienced a patient with IVL who tested positive for prostatic acid phosphatase (PAP), a marker of prostate cancer. Since then, we have regularly examined it when IVL was suspected to investigate usefulness of PAP as a diagnostic marker for IVL. We retrospectively evaluated usefulness of PAP as diagnostic marker of IVL. Design and methods: We reviewed clinical courses of 5 patients with IVL (3 males, 2 females) in comparison with 23 controls with hematologic malignancies other than IVL. Results: Serum levels of PAP were elevated in all of the 5 patients with IVL and 2 of the 23 controls. The difference was statistically significant using a chi-square test (p=0.0002). Sensitivity and specificity of PAP were 100% and 91%, respectively, in the diagnosis of IVL. Its serum levels were closely associated with disease status. Interpretation and conclusions: This study suggests that PAP might be a useful marker for the screening and assessment of disease activity and responses to the treatment of IVL.
Figure 1. Serum levels of PAP in IVL and other hematologic disease patients. Large spot shows median.
Haematologica 2004; 89:(4)e43-e45
Intravascular large B-cell lymphoma (IVL) is characterized by distribution of lymphoma cells predominantly or exclusively within the blood vessels. The clinical aspects of its presentation are puzzling, and it is difficult to unify into a single disease process. The classic presentation occurs in middle- or old-aged patients with a macular or papular rash and neurologic symptoms. Lymphadenopathy is rare, and fever, generalized weakness, and weight loss are frequent manifestations.1 IVL has another subtype, an Asian variant, which is characterized by hemophagocytic syndrome (HPS), pancytopenia, hepatosplenomegaly, and bone marrow involvement. It usually lacks any neurological or skin abnormalities, which are typical features of classical IVL.2 Bone marrow examination is a useful method for making definitive diagnosis. Without early diagnosis, the disease typically pursues aggressive and often fatal courses. IVL has been treated as fever of unknown origin (FUO),3 and many patients have been treated inadequately based on incorrect diagnoses. A 52 year-old male with FUO was admitted to Toranomon Hospital in 1987 (Case 1). Neither infections nor collagen diseases were probable causes of FUO. Physical and radiological examination did not show any evidence of malignant diseases. We determined serum levels of prostatic acid phosphatase (PAP) for the screening of prostate cancer. They were elevated to 4.7 µg/L (normal range